Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) Enterprise Value (2021 - 2025)

Lyra Therapeutics has reported Enterprise Value over the past 5 years, most recently at -$15.9 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$15.9 million for Q4 2025, up 60.83% from a year ago — trailing twelve months through Dec 2025 was -$15.9 million (up 60.83% YoY), and the annual figure for FY2025 was -$15.9 million, up 60.83%.
  • Enterprise Value for Q4 2025 was -$15.9 million at Lyra Therapeutics, up from -$22.1 million in the prior quarter.
  • Over the last five years, Enterprise Value for LYRA hit a ceiling of -$15.9 million in Q4 2025 and a floor of -$122.4 million in Q2 2022.
  • Median Enterprise Value over the past 5 years was -$69.3 million (2021), compared with a mean of -$66.9 million.
  • Biggest five-year swings in Enterprise Value: tumbled 146.78% in 2023 and later soared 64.38% in 2025.
  • Lyra Therapeutics' Enterprise Value stood at -$46.1 million in 2021, then tumbled by 115.48% to -$99.3 million in 2022, then decreased by 4.89% to -$104.1 million in 2023, then surged by 61.04% to -$40.6 million in 2024, then skyrocketed by 60.83% to -$15.9 million in 2025.
  • The last three reported values for Enterprise Value were -$15.9 million (Q4 2025), -$22.1 million (Q3 2025), and -$29.8 million (Q2 2025) per Business Quant data.